Dobutamine for patients with severe heart failure: A systematic review and meta-analysis of randomised controlled trials

Intensive Care Medicine

Volumn 38, Issue 3, 2012, Pages 359-367

  Tacon, Catherine L ^a   McCaffrey, John ^b   Delaney, Anthony ^a,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Dobutamine; Drugs; Heart failure; Inotropic agents; Meta analysis

Indexed keywords

DOBUTAMINE; PLACEBO;

BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; CARDIOTONIC AGENTS; DATABASES, BIBLIOGRAPHIC; DOBUTAMINE; HEART FAILURE; HUMANS; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862519619     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-011-2435-6     Document Type: Review

References (52)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society Of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388-2442. doi:10.1093/ eurheartj/ehn309
2. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M (2010) Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 122:1975-1996. doi: 10.1161/CIR.0b013e3181f9a223
3. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2011) Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF). Intensive Care Med. doi:10.1007/s00134-010-2113-0
4. CONSENSUS (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:1429-1435. doi: 10.1056/NEJM198706043162301
5. SOLVD (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:293-302. doi:10.1056/NEJM199108013250501
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717. doi: 10.1056/NEJM199909023411001
7. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21. doi: 10.1056/NEJMoa1009492
8. Rivero-Ayerza M, Theuns DA, Garcia- Garcia HM, Boersma E, Simoons M, Jordaens LJ (2006) Effects of cardiac resynchronization therapy on overall mortality and mode of death: a metaanalysis of randomized controlled trials. Eur Heart J 27:2682-2688. doi: 10.1093/eurheartj/ehl203
9. II CIBIS- (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13. doi:S0140673698111819
10. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP (1998) Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebocontrolled, randomized trials. Circulation 98:1184-1191
11. HF MERIT- (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet 353:2001-2007. doi:S0140673699044402
12. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658. doi: 10.1056/NEJM200105313442201
13. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199
14. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA (2005) Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 294:3124-3130. doi:10.1001/jama.294.24.3124
15. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G (2009) Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs 18:695-707. doi: 10.1517/13543780902922660
16. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A (2010) Inotropes in cardiac patients: update 2011. Curr Opin Crit Care 16:432-441. doi: 10.1097/MCC.0b013e32833e10fb
17. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR (2005) Optimal search strategies for retrieving scientifically strong studies of treatment from medline: analytical survey. BMJ 330:1179
18. Wong SS, Wilczynski NL, Haynes RB (2006) Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 94:41-47
19. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42-46
20. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412
21. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
23. Villar J, Mackey ME, Carroli G, Donner A (2001) Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med 20:3635-3647
24. Deeks JJ (2002) Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21:1575-1600
25. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT (2006) Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98:102-106
26. Adamopoulos S, Piepoli M, Qiang F, Pissimissis E, Davies M, Bernardi L, Forfar C, Sleight P, Coats A (1995) Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 345:344-349
27. Bader FM, Gilbert EM, Mehta NA, Bristow MR (2010) Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail 16:265-270. doi:10.1111/j.1751-7133.2010.00185.x
28. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6:501-508
29. Dies F, Krell MJ, Whitlow P, Liang C-S, Goldenberg I, Applefield MM, Gilbert EM (1986) Intermittent dobutamine in ambulatory outpatients with chronic heart failure. Circulation 74:II-38
30. Elis A, Bental T, Kimchi O, Ravid M, Lishner M (1998) Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 63:682-685
31. Erlemeier HH, Kupper W, Bleifeld W (1992) Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance. Cardiovasc Drugs Ther 6:391-398
32. Leier CV, Huss P, Lewis RP, Unverferth DV (1982) Drug-induced conditioning in congestive heart failure. Circulation 65:1382-1387
33. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB (1984) Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 69:113-119
34. Nanas JN, Tsagalou EP, Kanakakis J, Nanas SN, Terrovitis JV, Moon T, Anastasiou-Nana MI (2004) Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest 125:1198-1204
35. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903-1912
36. Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, Mauri F (1999) Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138:247-253
37. Sindone AP, MacDonald PS, Keogh AM (1998) Haemodynamic, neurohumoral and symptomatic effects of dobutamine, dopamine and milrinone in severe heart failure. [abstract]. Aust N Z J Med 28:113
38. Wimmer A, Stanek B, Kubecova L, Vitovec J, Spinar J, Yilmaz N, Kos T, Hartter E, Frey B, Pacher R (1999) Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J 40:321-334
39. Grose R, Strain J, Greenberg M, LeJemtel TH (1986) Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 7:1107-1113
40. Petersen JW, Felker GM (2008) Inotropes in the management of acute heart failure. Crit Care Med 36:S106-S111. doi:10.1097/01.CCM.0000296273.72952.39
41. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788
42. Dar O, Cowie MR (2008) Acute heart failure in the intensive care unit: epidemiology. Crit Care Med 36:S3-S8. doi:10.1097/01.CCM.0000296264.41365.80
43. Lehtonen LA, Antila S, Pentikainen PJ (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43:187-203
44. Chalmers I (1990) Underreporting research is scientific misconduct. JAMA 263:1405-1408
45. Shields PG (2000) Publication bias is a scientific problem with adverse ethical outcomes: the case for a section for null results. Cancer Epidemiol Biomarkers Prev 9:771-772
46. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-e34. doi: 10.1016/j.jclinepi.2009.06.006
47. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46:57-64. doi:10.1016/j.jacc.2005.03.051
48. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37:290-301. doi:10.1007/s00134- 010-2073-4
49. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997-1003
50. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297:1883-1891
51. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R (2010) Levosimendan for the treatment of acute severe heart failure: A metaanalysis of randomised controlled trials. Int J Cardiol 138:281-289. doi: 10.1016/j.ijcard.2008.08.020
52. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update: ACCF/ AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:1977-2016. doi:10.1161/CIRCULATIONAHA.109. 192064